Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors
NCT07226713
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Pacritinib
Sponsor
Medical College of Wisconsin